- Home
- PENN vs IMVT Comparison
PENN vs IMVT Comparison
Compare PENN & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PENN
- IMVT
- Stock Information
- Founded
- PENN 1972
- IMVT 2018
- Country
- PENN United States
- IMVT United States
- Employees
- PENN N/A
- IMVT N/A
- Industry
- PENN Hotels/Resorts
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PENN Consumer Discretionary
- IMVT Health Care
- Exchange
- PENN Nasdaq
- IMVT Nasdaq
- Market Cap
- PENN 2.8B
- IMVT 2.7B
- IPO Year
- PENN 1994
- IMVT N/A
- Fundamental
- Price
- PENN $19.21
- IMVT $15.15
- Analyst Decision
- PENN Buy
- IMVT Buy
- Analyst Count
- PENN 19
- IMVT 11
- Target Price
- PENN $22.89
- IMVT $33.88
- AVG Volume (30 Days)
- PENN 3.1M
- IMVT 1.7M
- Earning Date
- PENN 11-06-2025
- IMVT 11-06-2025
- Dividend Yield
- PENN N/A
- IMVT N/A
- EPS Growth
- PENN N/A
- IMVT N/A
- EPS
- PENN N/A
- IMVT N/A
- Revenue
- PENN $6,745,700,000.00
- IMVT N/A
- Revenue This Year
- PENN $8.34
- IMVT N/A
- Revenue Next Year
- PENN $5.53
- IMVT N/A
- P/E Ratio
- PENN N/A
- IMVT N/A
- Revenue Growth
- PENN 7.33
- IMVT N/A
- 52 Week Low
- PENN $13.25
- IMVT $12.72
- 52 Week High
- PENN $23.08
- IMVT $32.10
- Technical
- Relative Strength Index (RSI)
- PENN 49.81
- IMVT 44.88
- Support Level
- PENN $18.67
- IMVT $15.09
- Resistance Level
- PENN $19.36
- IMVT $15.82
- Average True Range (ATR)
- PENN 0.57
- IMVT 0.81
- MACD
- PENN -0.18
- IMVT -0.06
- Stochastic Oscillator
- PENN 27.32
- IMVT 26.04
About PENN PENN Entertainment Inc.
Penn Entertainment's origins date back to its 1972 racetrack opening in Pennsylvania. Today, Penn operates 43 properties across 20 states and 12 brands, including Hollywood Casino and Ameristar. Land-based casinos represented 85% of total sales in 2024; 15% was from the interactive segment, which includes sports, iGaming, and media revenue. The retail portfolio generates mid-30s EBITDAR margins and helps position the company to obtain licenses for the digital wagering markets. Additionally, Penn's media assets, theScore and ESPN (starting with its partnership launch in November 2023), provide access to sports betting/iGaming technology and clientele, helping it form a leading digital position.
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.